Non-invasive imaging of Alzheimer Disease biomarkers in the brain and eye
Age related neurodegenerative diseases such as Alzheimer’s Disease (AD) affect ~500,000 Canadians, and the economic burden of dementia was $15 billion in 2008. Early diagnosis and novel therapies are needed to improve the quality of life of affected individuals, and to reduce costs to the Canadian health care system. However, screening for irreversible hallmarks of neurodegeneration before onset of symptoms currently requires brain imaging with expensive equipment or invasive techniques.
We propose to develop technology to non-invasively image amyloid beta and degeneration in the eyes of mouse model of AD, and compare it to changes in the brain tissues. This technology can be adapted to human imaging where it can potentially be used for early detection of AD before the onset of cognitive impairment.
The Pacific Alzheimer Research Foundation (PARF) and the Alzheimer Society of Canada (ASC) agreed to co-fund research grants through the 2013 Alzheimer Society Research Program (ASRP) competition. This was one of the projects being awarded a grant. > Learn more…